Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 10/20 | 0.76 |
| ▸ | HGFAC | Q04756 | 4/20 | 0.76 |
| ▸ | F2 | P00734 | 4/20 | 0.76 |
| ▸ | F12 | P00748 | 4/20 | 0.76 |
| ▸ | C1R | P00736 | 2/20 | 0.76 |
| ▸ | F10 | P00742 | 2/20 | 0.76 |
| ▸ | KLK1 | P06870 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.76 |
| ▸ | MLNR | O43193 | 1/20 | 0.76 |
| ▸ | PLG | P00747 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.76 |
| ▸ | HPN | P05981 | 1/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.76 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.76 |
| ▸ | C1S | P09871 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nafamostat SCHEMBL29360143 | 0.86 | PRSS1 (1.00) | PRSS1HGFACF2F12C1R | |
| Nafamostat SCHEMBL135504 | 0.86 | PRSS1 (1.00) | PRSS1HGFACF2F12C1R | |
| Nafamostat SCHEMBL29358879 | 0.86 | PRSS1 (1.00) | PRSS1HGFACF2F12C1R | |
| Nafamostat SCHEMBL1650158 | 0.85 | FTO (1.00) | PRSS1HGFACF2F12C1R | |
| Nafamostat SCHEMBL25197320 | 0.85 | FTO (1.00) | PRSS1HGFACF2F12C1R | |
| SCHEMBL9825106 | 0.83 | PRSS1 (0.58) | PRSS1HGFACF2F12C1R | |
| SCHEMBL31380450 | 0.82 | F12 (0.76) | PRSS1HGFACF2F12C1R | |
| SCHEMBL14294845 | 0.80 | PRSS1 (0.59) | PRSS1HGFACF2F12C1R | |
| SCHEMBL9824643 | 0.79 | FTO (0.64) | PRSS1HGFACF2F12C1R | |
| Hydrochloric Acid SCHEMBL9825728 | 0.79 | FTO (0.63) | PRSS1HGFACF2F12C1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190697-A1 | METHODS FOR TREATING VIRAL INFECTIONS WITH NAFAMOSTAT | ENSYSCE BIOSCIENCES, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190697-A1 | METHODS FOR TREATING VIRAL INFECTIONS WITH NAFAMOSTAT | ACE2, ACE, PRSS2 | PRSS1 9/4885HGFAC 2637/4885F2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.